Drugmakers are raising an alarm about shortages in Greece as the possibility of a "Grexit" looms. That "worst-case scenario" could put supplies in peril, the European Federation of Pharmaceutical Industries and Associations warned European Commission officials, with suddenly cheap meds in Greece diverted for sale at higher prices in neighboring EU countries.
Sterile injectable drugs are notoriously tricky to manufacture. Mylan has found that out the hard way, and it's now expanding a recall of cancer drugs that it began in April because they may contain particulate.
AstraZeneca CEO Pascal Soriot has made emerging markets part of his 5-point campaign to rebuild the drugmaker's financial health. And now he is taking that piece of his campaign to North Africa, where AstraZeneca is part of a joint venture to build a $125 million plant.
A groundbreaking ceremony was held Wednesday for the $1.2 billion National Bio and Agro-Defense Facility (NABF) currently under construction in Kansas.
AstraZeneca CEO Pascal Soriot is counting on the company's cancer drug pipeline to help it climb out of the revenue hole it has fallen into, and he figures his company needs more manufacturing capacity for the coming launches.
Rare disease drugmaker Alexion has found a lot to love in Ireland. Taking advantage of that country's generous tax rate, it has turned that country into its European base of operations. With a pipeline of new drugs brewing, the rare disease specialist now intends to build a new plant and add a couple hundred more workers there.
Animal health leader Zoetis is using a move out of the Amgen playbook, whacking on manufacturing to cut costs and appease an aggressive activist investor.
WuXi Biologics is embarking on construction of what will be the biggest biologics plant in China once it's completed--an event the company expects by the end of next year.
Mylan is recalling 8 lots of injectable cancer drugs, most of them manufactured for Pfizer, after particulate was discovered in vials.
J&J's Janssen unit is recalling one lot of Ortho-Cept contraceptive tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.